Rizatriptan 10 MG RPD in the Treatment of Acute Migraine

NCT01057160 | Completed Phase 4

• 1 other identifier: MK 462
• Study Type: interventional
• Target: 195
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.

Conditions

Migraine

Outcome Measures

Primary Outcomes (1)

• Percentage of patients with headache response on a one to four scale after 2 hours.

  2 hours

Secondary Outcomes (1)

• Percentage of patients being headache free two hours after intake of study medication. Time of dosing to onset of headache relieve. Relief of concomitant symptoms. Rate of sustained pain free Percentage of patients needing rescue medication

  (time points 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours after drug intake

Study Arms (2)

intake of rizatriptan 10 mg

EXPERIMENTAL

Drug: Rizatriptan

previous used analgesic

ACTIVE COMPARATOR

Drug: Rizatriptan

Interventions

Rizatriptan DRUG

use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic

intake of rizatriptan 10 mg; previous used analgesic

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient's signature on the informed consent document \[each patient should be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the trial and have a clear understanding of the trial and the procedures involved prior to the signing of the consent form\].
• Have a clinical diagnosis of migraine with or without aura according to IHS criteria at least one year prior to enrollment.
• At screening a stable dose of prophylactic medication (including no prophylactic treatment) for at least two months and no change of prophylactic medication during active trial period.

You may not qualify if:

• Contraindication to triptans or Rizatriptan according to medical information sheet.
• Patient has a history or clinical evidence of ischemic heart disease (e.g., angina pectoris of any type, history of myocardial infarction or documented silent ischemia) or symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm (including Prinzmetal's variant angina), or other significant underlying cardiovascular disease. Patient has uncontrolled hypertension. Patient has either demonstrated hypersensitivity to or experienced a serious adverse event in response to Rizatriptan or any of its inactive ingredients.
• History of treatment failure for at least one triptan for the treatment of acute migraine attacks.
• Any other headache, except tension type headache on 5 or less days a month within three months prior to screening.
• A history of drug induced headache, medication overuse headache or any other addiction.
• Any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial.
• Females of childbearing potential not using reliable means of birth control, pregnant or lactating females or expected/ planned pregnancy.
• Participation (planned or current) in any investigational drug or device trial within the previous 30 days prior to screening visit.
• Inability to understand the trial procedures, and thus inability to give informed consent.
• History of allergy to sulfa drugs.

Sponsors & Collaborators

• Universität Duisburg-Essen: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

Department of Neurology, University Hospital Essen

Essen, 45147, Germany

Location

MeSH Terms

Conditions

Migraine Disorders

Interventions

rizatriptan

Condition Hierarchy (Ancestors)

Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Hans-Christoph Diener, Prof.

  Department of Neurology, University Essen

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof. of Neurology

Study Record Dates

• First Submitted: January 26, 2010
• First Posted: January 27, 2010
• Study Start: May 1, 2008
• Primary Completion: June 1, 2010
• Study Completion: June 1, 2010
• Last Updated: January 28, 2013

Record last verified: 2013-01

Locations

DE (1)